ASCO releases new recommendations amid growing therapeutic options and fresh concerns about serious skeletal-related events.
The American Society of Clinical Oncology (ASCO) has developed a new set of recommendations for using bone-modifying agents for patients with metastatic breast cancer amid growing therapeutic options and fresh concerns about serious skeletal-related events.
The ASCO panel said only patients with evidence of bone metastases should be treated with the therapy, and that there is insufficient evidence to demonstrate greater efficacy of 1 bone-modifying agent over another.
The options are: denosumab 120 mg subcutaneously every 4 weeks; intravenous pamidronate 90 mg over no fewer than 2 hours; or zoledronic acid 4 mg over no fewer than 15 minutes every 3 to 4 weeks. Serum creatinine should be monitored before each dose, and patients should receive dental care before and during therapy.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
Workflow, Educational Tools Improve Use of Silicone Film to Prevent Radiation Dermatitis
April 25th 2024Tools to educate oncology nurses and patients on the use of Mepitel film to prevent radiation dermatitis has improved the workflow around its introduction to patients with breast cancer, as well as its application and maintenance.